Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites

Cited by (130)

Items 101–130 of 130

1. Leberzirrhose und Komplikationen rechtzeitig erkennen
   Manfred Gross · 2019 · MMW - Fortschritte der Medizin
2. Impact of small intestinal bacterial overgrowth on systemic inflammation, circulatory and renal function, and liver fibrosis in patients with cirrhosis and ascites
   Olga Alexiou · 2024 · Annals of Gastroenterology
3. Comprehensive approach to liver cirrhosis treatment: Integrating ayurveda, homeopathy, and allopathy
   Debabrata Dash, Palak Kesharwani, Raj Kumar Koiri · 2025 · Pharmacological Research - Natural Products
4. Novel Targets and Drug Development in Portal Hypertension
   Robert Schierwagen, Sabine Klein, Frank Erhard Uschner, Jonel Trebicka · 2019 · Current Hepatology Reports
5. NON-ANTIBIOTIC USE OF ANTIBIOTICS
   Maciej Danielewski, Dorota Ksiądzyna, Adam Szeląg · 2018 · Postępy Mikrobiologii - Advancements of Microbiology
6. Future Pharmacological Therapies of Portal Hypertension
   Guillermo A. Ortiz, Guadalupe García–Tsao · 2019 · Current Hepatology Reports
7. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
   Rooshi Nathwani, Benjamin Harvey Mullish, David Koeckerling, Alexander Cole, Nowlan Selvapatt, Ameet Dhar · 2021 · European Medical Journal
8. Acute-on-chronic liver failure: an update
   Sebastián Marciano, EM Mauro, Gadano Ac · 2013
9. Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis
   Asmaa Naser Mohammad, Mahmoud Kamal Elsamman, Amr Zaghloul, Hameda Hassan Mohamed, Walaa Mohammed · 2018 · The Egyptian Journal of Internal Medicine
10. Intestinal barrier dysfunction and alcoholic liver disease
    Zhao-Chun Chi · 2019 · World Chinese Journal of Digestology
11. Myocardial Injury Secondary to Intestinal Ischemia/Reperfusion or Microbiota Disturbance: Preventive and Therapeutic Concerns
    Emmanuel E. Douzinas, Aikaterini Apeiranthitis · 2019 · Springer eBooks
12. Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
    Sergey Kensarinovich Zyryanov, Байбулатова Елена Александровна · 2020 · Antibiot Khimioter = Antibiotics and Chemotherapy
13. Effect of rifaximin in the prevention of acute kidney injury and hepatorenal syndrome type II in Egyptian cirrhotic patients
    Ahmed El-Gebaly, Nermin Saad Ghanem, Ahmed A. Abdelmoaty · 2021 · Zagazig University Medical Journal
14. Investigational drugs in early clinical development for portal hypertension
    Susana Gomes Rodrigues, Yuly Paulin Mendoza, Jaime Bosch · 2022 · Expert Opinion on Investigational Drugs
15. Intestinal permeability and its role in the pathogenesis and progress of non-alcoholic fatty liver disease. Review
    Oleksiy Gridnyev, G. D. Fadieienko, I. Е. Kushnir, S. V. Gridnieva · 2023 · Modern Gastroenterology
16. Reply to: “Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease”
    Benedikt Simbrunner, Dalila Costa, Thomas Reiberger · 2021 · Journal of Hepatology
17. Treatment Options for Covert Hepatic Encephalopathy
    Nisheet Waghray, Abhijeet Waghray, Kevin D. Mullen · 2014 · Current Treatment Options in Gastroenterology
18. Antifibrotic Therapy for Liver Cirrhosis
    Lê Thị Thanh Thủy, Hoang Hai, Vu Ngoc Hieu, Ninh Quoc Dat, Dinh Viet Hoang, Norifumi Kawada · 2019 · Springer eBooks
19. Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy
    Mitsuhiko Shibasaki, Takeshi Hatanaka, Yasushi Shimada, Tamon Nagashima, Masashi Namikawa, Shuichi Saito, Kenichi Hosonuma, Atsushi Naganuma, Daichi Takizawa, Hirotaka Arai et al. · 2019 · Kanzo
20. Predictors of hepatorenal syndrome in patient with decompensated liver cirrhosis
    Sanjit Karki, Roshan Shrestha, Manoj Shah, Ramila Shrestha, Bidhan Nidhi Paudel · 2021 · Journal of General Practice and Emergency Medicine of Nepal
21. Portosystemic Encephalopathy
    Jawaid Ahmed Shaw, Jasmohan Singh Bajaj · 2016 · Springer eBooks
22. A Tour-d’Horizon of microbiota therapeutics for metabolic disorders
    Sheeba Saifi, Aparna Swaminathan, Priti Devi, Partha Chattopadhyay, Saksham Gupta, Aarushi Garg, Saransh Saxena, Shaista Parveen, Rajesh Pandey · 2023 · Elsevier eBooks
23. Kidney–Gut Crosstalk in Acute Kidney Injury
    Ramiro Cruz González Sueyro · 2023 · Springer eBooks
24. Piperacillin-Tazobactam Versus Piperacillin-Tazobactam Plus Rifaximin for the Treatment of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis: A Prospective Comparative Open-Label Interventional Study
    Pukar Thapa · 2022 · Advanced Research in Gastroenterology & Hepatology
25. Simvastatin and Rifaximin to Prevent Acute-on-Chronic Liver Failure in Decompensated Cirrhosis: A Double Blind, Randomized Trial
    Elisa Pose, César Jiménez, Giacomo Zaccherini, Daniela Campion, Salvatore Silvio Piano, Frank Erhard Uschner, Koos de Wit, Olivier Roux, Kohilan Gananandan, Wim Laleman et al. · 2024 · SSRN Electronic Journal
26. Severe Alcoholic Hepatitis-optimizing Medical Management: Whether we need a Liver Transplant
    Harshal Rajekar · 2024 · Annals of Clinical Gastroenterology and Hepatology
27. Disease Modulating Agents in Cirrhosis
    Vinay Jahagirdar, Jasmohan Singh Bajaj · 2025 · Clinics in Liver Disease
28. Single Session of Fecal Microbiota Transplantation in Decompensated Cirrhosis: An open-label randomized control trial
    Akash Roy, Madhumita Premkumar, Anima Sharma, Nipun Verma, Surender Singh, Arka De, Madhu Chopra, Sunil Taneja, Ajay Duseja, Radha Krishan Dhiman · 2021 · Research Square
29. Gut Feeling: Microbiota as a Hidden Regulator of Hypertension
    Lovepreet Singh, Gurman Bhullar, Sonia Shaik, Varsha Ganesh, Hemanth Kesani, Manju Rai · 2026 · Journal of Nutrition
30. Evaluation of Kidney Function in Cirrhosis: Methods and Pitfalls
    Fernando Gil-Lopez, Namrata Parikh, Martin L. Mai, Răzvan M. Chirilă, Hani M. Wadei · 2026 · Diagnostics